Connect with us

Healthcare

Shilpa Medicare Limited (shilpamed) Q4 FY26: Revenue Up 30%, Ebitda Surges 40%

Shilpa Medicare Limited (SHILPAMED) reports Q4 FY26 earnings with revenue up 30% and EBITDA surging 40%.

Shruti singh - TradeAlone

Published

on

Shilpa Medicare Limited Q4 FY26 Results

Shilpa Medicare Limited (SHILPAMED) has announced its Q4 FY26 earnings, showcasing a robust performance with revenue up 30% and EBITDA surging 40% year-on-year. The company’s strong momentum continues to accelerate as it closes FY26 on a solid footing. For the quarter, the company delivered its highest-ever quarterly revenue at INR 439 crores, driven by growth in Formulation Drug Products (FDF) and Biologics segments.

Financial Highlights

The financial highlights for Q4 FY26 include:

  • Highest quarterly revenue at INR 439 crores, a robust 30% increase on a year-on-year basis.
  • Highest quarterly EBITDA at INR 121 crores, growing 40% YoY.
  • EBITDA margins at 28%, improving by ~200 bps YoY.
  • Adjusted PAT came in at INR 87 crores, growing at ~147% YoY.

Full Year FY26 Performance

For FY26, Shilpa Medicare Limited delivered its highest-ever annual revenue of INR 1,549 crores, registering a growth of 18% on a year-on-year basis. The company’s gross margins improved by 100 bps to 70%, attributed to a favorable product mix. The highest-ever annual EBITDA of INR 445 crores was achieved, growing 30% YoY; EBITDA margins improved by ~300 bps to 29% YoY. The adjusted PAT at INR 232 crores grew ~135% YoY, demonstrating significant bottom-line acceleration.

Looking Ahead

With a strong R&D pipeline and strategic partnerships fueling market share gains, Shilpa Medicare Limited is on track for a stronger FY27. The company is leveraging its differentiated manufacturing platform with the expected launch of its first transdermal patch product in the EU in the coming quarters and its first-ever transdermal patch submission to the USFDA completed during 4QFY26. The company’s improving Return on Capital Employed (ROCE) reflects how operational momentum is translating into greater capital efficiency.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Shilpa Medicare Limited

Shilpa Medicare Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

SHILPAMED
Healthcare › Drug Manufacturers - Specialty & Generic
CONSOLIDATING DOWN
54
Fundamental
74
Technical
64
Overall

1W -14.36%
1M -3.09%
3M +4.92%
P/E: 49.7 Cap: Mid
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Shilpa gains 46.1% over three months and trades near its 52-week highs. The PEG stands at 4.72 — severely stretched. Any earnings miss could trigger a sharp de-rating. No meaningful dividend — total return is entirely dependent on capital appreciation. RSI hits 70, a level that signals the stock runs hot. Notably, buyers drove volume on 16 recent sessions — though at these levels, some profit-taking is normal. The stock rises 46.1% in three months. Yet revenue grows at only 4.1% and the PEG stands at 4.72. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Shilpa Medicare Limited.

Healthcare

Natco Pharma Limited Receives Positive FDA Inspection Report for Visakhapatnam Plant

Natco Pharma Limited (NSE: NATCOPHARM) receives positive FDA inspection report for Visakhapatnam plant, classifying it as Voluntary Action Indicated (VAI).

Shruti singh - TradeAlone

Published

on

Natco Pharma Limited Natcopharm Positive FDA Inspection

Natco Pharma Limited (NSE: NATCOPHARM) announced today the receipt of a positive Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its Visakhapatnam plant. The inspection, conducted from August 17th to August 21st, 2026, resulted in the classification of the inspection as Voluntary Action Indicated (VAI), indicating minor observations. The company received four observations in the Form 483 during the inspection.

Positive Outcome

The positive outcome of the FDA inspection is a significant milestone for Natco Pharma Limited, reinforcing the company’s commitment to maintaining high standards in its manufacturing processes. The classification as VAI suggests that while there are minor areas for improvement, the overall compliance with regulatory standards is satisfactory.

Commitment to Quality

Natco Pharma Limited continues to prioritize quality and regulatory compliance in its operations. The company’s manufacturing facilities are approved by several leading regulatory authorities, including the U.S. FDA, Brazil ANVISA, Health Canada, and WHO, serving over 50 global markets. The positive FDA report further solidifies the company’s reputation for producing high-quality pharmaceuticals.

Natco Pharma Limited remains dedicated to its mission of developing, manufacturing, and distributing generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients, and crop protection products. The company’s R&D-oriented approach and science-driven focus enable it to lead in targeted therapies, particularly in oncology, both domestically and internationally.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Natco Pharma Limited

Natco Pharma Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

NATCOPHARM
Healthcare › Drug Manufacturers - Specialty & Generic
APPROACHING RESISTANCE
80
Fundamental
66
Technical
73
Overall

1W +0.48%
1M +1.68%
3M -8.49%
P/E: 17.7 Cap: Mid
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Natco trades in the lower quarter of its 52-week range. The PEG of 0.70 signals undervaluation relative to growth. It is a potential re-rating candidate. Industry-leading margins of 26.8% reflect exceptional pricing power and operational efficiency. Buyers show up with 1.9x the volume of sellers. Moreover, they dominated on 16 of recent sessions versus 14 for sellers — a healthy accumulation pattern. Revenue grows at 14.5% and profits at 25.6% CAGR, with D/E of 0.03. Meanwhile, the stock dips 7.6% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Natco Pharma Limited.

Continue Reading

BETA

Beta Drugs Limited Forms Oncology Joint Venture with IMGSA Groupe SPA

Beta Drugs Limited forms oncology joint venture with IMGSA Groupe SPA, acquiring oncology plant for US$8.7 million.

adit chauhan author tradealone

Published

on

Beta Drugs Limited BETA Oncology JV IMGSA

Beta Drugs Limited (“Beta”) today announced that it has entered into a joint venture (“JV”) with IMGSA Groupe SPA (“IMGSA”), a leading pharmaceutical company in Algeria. Beta will hold a 49% stake in the JV, acquiring IMGSA’s oncology formulation plant for US$8.7 million. This strategic move aims to deepen the partnership and build a strong oncology business in Algeria and North African markets.

Transaction Details

The JV will acquire the oncology plant from IMGSA for US$8.7 million. Part of the consideration will be settled by issuing equity shares to IMGSA. Beta will infuse US$3 million over three years and transfer formulation technology to the JV. The plant has manufacturing capabilities for both injectable and oral solid dosage forms, enabling the JV to produce a range of oncology products locally in Algeria.

Market Positioning

The Algerian oncology market is valued at approximately US$1 billion and growing rapidly. The JV is well positioned to capture significant market share in national tenders by combining Beta’s research, development, manufacturing, and supply chain capabilities with IMGSA’s marketing and distribution infrastructure. The Algerian government incentivizes local manufacturing of critical life-saving pharmaceutical products, further supporting the JV’s growth.

Rahul Batra, MD of Beta Drugs Limited, said: “Our relationship with IMGSA has grown steadily over many years, and this joint venture marks a natural next step for us to deepen our relationship and commitment to the Algerian market. By bringing our manufacturing technology and know-how to a well-equipped oncology plant and pairing it with IMGSA’s strong market presence in Algeria, we aim to improve access to quality cancer therapies for patients in Algeria.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Beta Drugs Limited

Beta Drugs Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

BETA
Healthcare › Drug Manufacturers - Specialty & Generic
CONSOLIDATING DOWN
60
Fundamental
66
Technical
64
Overall

1W -8.91%
1M -3.73%
3M -31.96%
P/E: 33.3 Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Beta falls 25.9% over three months and has not found a floor yet. The PEG reaches 3.48. The stock trades on brand and index weight, not on growth. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gains 4.8% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 19.2% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Beta Drugs Limited.

Continue Reading

Health Information Services

Indegene Limited (indgn) Becomes First Industry Partner of Indo-uk Life Science Corridor

Indegene Limited (INDGN) announced as the first industry partner for the Indo-UK Life Science Corridor, connecting India and UK research.

preety tomer tradealone

Published

on

Indegene Limited INDGN First Industry Partner Indo-uk Life Science Corridor

Indegene Limited (INDGN) has been announced as the first industry partner for the Indo-UK Life Science Corridor, a collaboration between the Centre for Cellular and Molecular Platforms (C-CAMP) and Imperial College London. This initiative, supported by the Imperial Global India initiative, aims to connect world-class research in India and the UK with entrepreneurship, industry expertise, and pathways to translation. The corridor is designed to facilitate the two-way sharing of knowledge and evidence on priority challenges, innovation readiness, and ecosystem needs.

Strategic Collaboration

Indegene, C-CAMP, and Imperial College London will co-develop entrepreneurship programs and support the exchange of knowledge and talent between India and the UK. Indegene, an AI-native operating partner for modern life sciences, brings deep industry context to the corridor and has a track record of working with the world’s top 20 biopharma companies. As part of the collaboration, Indegene will help define industry challenges and support startup exchanges and ecosystem immersion programs.

Focus Areas

Initial focus areas include antimicrobial resistance, diagnostics, digital health, agritech, brain science, and mental health. The three organizations made the announcement at the C-CAMP–Imperial joint Roundtable on International Partnerships for AI Discovery and Innovation, convened under the Government of Karnataka’s Global Innovation Alliance initiative as part of the Bengaluru Tech Summit 2026.

The partnership reflects Indegene’s commitment to support deep science, strengthen translation pathways, and help promising innovation reach scale. This collaboration is expected to produce smarter, more scalable, and more accessible innovations relevant to both populations.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Indegene Limited

Indegene Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

INDGN
Healthcare › Health Information Services
BREAKOUT
62
Fundamental
80
Technical
71
Overall

1W -1.28%
1M +11.79%
3M +17.07%
P/E: 38.7 Cap: Mid
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Indegene gains 15.9% over three months and trades near its 52-week highs. The PEG of 2.41 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gives back 2.0% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock rises 15.9% in three months on 15.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Indegene Limited.

Continue Reading

Trending

Exit mobile version